Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Hold" from Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $4.78.

A number of equities analysts have recently issued reports on IRWD shares. Jefferies Financial Group reiterated a "hold" rating and set a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Craig Hallum cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of IRWD. SG Americas Securities LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $53,000. EMC Capital Management raised its holdings in Ironwood Pharmaceuticals by 693.0% during the fourth quarter. EMC Capital Management now owns 23,893 shares of the biotechnology company's stock worth $106,000 after buying an additional 20,880 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock valued at $150,000 after purchasing an additional 3,209 shares in the last quarter. Journey Strategic Wealth LLC purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth $45,000. Finally, Rhumbline Advisers raised its holdings in Ironwood Pharmaceuticals by 3.0% during the 4th quarter. Rhumbline Advisers now owns 348,006 shares of the biotechnology company's stock valued at $1,542,000 after acquiring an additional 10,041 shares during the period.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD traded up $0.00 during mid-day trading on Friday, hitting $0.61. 121,705 shares of the stock traded hands, compared to its average volume of 3,339,357. The stock has a fifty day moving average price of $0.85 and a 200-day moving average price of $2.22. The company has a market cap of $98.87 million, a price-to-earnings ratio of -20.37 and a beta of 0.37. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $41.14 million during the quarter, compared to analysts' expectations of $67.02 million. As a group, sell-side analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.